Table 1 Demographic and clinical characteristics of patients undergoing PreserfloTM MicroShunt.
No. Eyes/patients | 100/91 |
Age, years, mean (±SD) | 67.9 (±12.1) |
Ethnicity, n (%) | |
European descent | 86 (95%) |
African descent | 3 (3%) |
Asian descent | 2 (2%) |
Gender, male/female | 52/39 |
Eye, right/left | 53/47 |
Baseline BCVA, median (IQR)a | 0.1 (0.0–0.2) |
Baseline IOP, median (IQR) | 22 (19–28) |
Number of glaucoma drops, median (IQR) | 3 (2–3) |
Acetazolamide, no eyes (%) | 20 (20%) |
Glaucoma subtype, no eyes (%) | |
POAG | 70 (70%) |
Pseudoexfoliative glaucoma | 13 (13%) |
Pigmentary glaucoma | 7 (7%) |
Normal-tension glaucoma | 5 (5%) |
PACG | 3 (2%) |
Uveitic glaucoma | 2 (2%) |
Lens status, no eyes (%) | |
Phakic | 69 (69%) |
Pseudophakic | 31 (31%) |
Previous LTP, no eyes (%) | 15 (15%) |
Previous VR Surgery, no eyes (%) | 5 (5%) |
Previous Glaucoma Surgery (±CEIOL), no eyes (%) | |
Trabeculectomy | 4 (4%) |
Cypass | 3 (3%) |
Xen Gel Stent | 2 (2%) |
Viscocanalostomy | 2 (2%) |
Transscleral Cyclophotocoagulation | 3 (3%) |
Canaloplasty | 1 (1%) |
Istent Inject | 1 (1%) |
